Provided is a superconducting magnet device comprising: a winding frame; a superconducting coil that is configured by winding a tape-shaped superconducting wire on the winding frame; and a buffer member that suppresses torsional deformation which is caused by flow of a transport current to the superconducting coil.
A tissue cell parameter processing device (101) estimates a tissue cell parameter from images obtained by imaging an affected area. In this estimation, a reception unit (102) receives a low-load image obtained by imaging the affected area under a low-load condition. A generation unit (103) feeds the low-load image as input into a trained generative model, and thus generates a high-load image that would be obtained by imaging the affected area under a high-load condition. An estimation unit (104) estimates a tissue cell parameter pertaining to the affected area from the high-load image. A control unit (105), which can be omitted, executes the processing by the reception unit (102), the generation unit (103), and the estimation unit (104) on a plurality of low-load images respectively obtained by imaging the affected area at different times, so that the tissue cell parameter at the different times is estimated. A prediction unit (106), which can be omitted, feeds the tissue cell parameter at the different times as input into a trained predictive model, and thus interpolates and predicts temporal changes in the tissue cell parameter.
This method for predicting the effectiveness of dupilumab administration to an atopic dermatitis patient comprises a step for measuring the concentration of at least one biomarker in a blood sample derived from the patient before dupilumab administration, wherein: the concentration of the biomarker is an indicator for predicting the effectiveness of the dupilumab administration; and the biomarker is selected from the group consisting of interleukin (IL)-22, C-C Motif Chemokine Ligand (CCL) 20, IL-18, IL-17, Tumor Necrosis Factor (TNF)-α, and C-X-C Motif Chemokine 9 (CXCL9).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
4.
METHOD FOR IDENTIFYING FUNCTIONAL CELL SUBPOPULATIONS IN MESENCHYMAL/STEM CELL POPULATIONS
JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (Japan)
KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
RIKEN (Japan)
Inventor
Sato, Yoji
Miura, Takumi
Takano, Megumi
Umezawa, Akihiro
Kawai, Jun
Kouno, Tsukasa
Ito, Masayoshi
Abstract
The present invention provides a method for identifying functional cell subpopulations in an MSCs cell population, the method comprising performing omics analysis of an MSCs cell population at the single cell level and clustering the MSCs cell population based on the results of the analysis to classify the cell population into cell subpopulations.
Provided is: an oxygen generating electrode in which a high electrolytic current density can be obtained even with a content of a noble metal within a certain range, the oxygen generating electrode comprising a catalyst containing an iridium-containing manganese oxide combined with a conductive base material containing platinum; and/or a water electrolysis method using the electrode. The oxygen generating electrode comprises a conductive base material and a catalyst containing an iridium-containing manganese oxide. The conductive base material contains platinum, the total of the amount of iridium per geometric area of the oxygen generating electrode and the amount of platinum per geometric area of the oxygen generating electrode is above 0.1 mg/cm2and 6.1 mg/cm2 or less, and the ratio of the amount of platinum per geometric area of the oxygen generating electrode to the amount of iridium per geometric area of the oxygen generating electrode is 1 or more and less than 600.
C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
C25B 11/053 - Electrodes comprising one or more electrocatalytic coatings on a substrate characterised by multilayer electrocatalytic coatings
C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
6.
Magnetic Optical Trap Device, Physics Package, Physics Package for Optical Lattice Clock, Physics Package for Atomic Clock, Physics Package for Atomic Interferometer, Physics Package for Quantum Information Processing Device, and Physics Package System
According to the present invention, atoms are trapped by a quadrupole magnetic field formed by ring-shaped magnets and three sets of laser beam pairs. A portion of the laser beam pairs is partially blocked by the ring-shaped magnets, , so that a region which is a non-atom trap space is formed inside an intersecting region where the three groups of laser beam pairs cross. The inside of the intersecting region is irradiated with a laser beam so that atoms within the non-atom catch space are extracted from the intersecting region.
G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks
H03L 7/26 - Automatic control of frequency or phaseSynchronisation using energy levels of molecules, atoms, or subatomic particles as a frequency reference
7.
METHOD AND KIT FOR PREDICTING EFFICACY OF DUPILUMAB ADMINISTRATION TO ATOPIC DERMATITIS PATIENT
Provided is a method for predicting the efficacy of dupilumab administration to an atopic dermatitis patient, the method comprising a step for measuring the expression level of at least one biomarker in a skin tissue sample from the patient prior to dupilumab administration, wherein the expression level of the biomarker is an indicator for predicting the efficacy of dupilumab administration.
The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
Provided are a small animal excreta recovery device and a small animal rearing cage equipped with the small animal excreta recovery device. This small animal excreta recovery device comprises: a rotation mechanism that, for each preset set time, rotates a disk-shaped turntable having a container for accommodating excreta; and a distribution mechanism that distributes a member for closing the container accommodating the excreta.
To provide a surface-emitting quantum cascade laser that can easily achieve high power with low divergence operation, the PhC-QCL element of the present disclosure has a first electrode, which is a film extending beyond a certain range, a semiconductor superlattice structure, and a second electrode disposed on or above the semiconductor superlattice structure. The semiconductor superlattice structure has an active region comprising a plurality of unit structures that are repeatedly stacked. The second electrode has an array of apertures that forms, for example, a triangular lattice. The second electrode has no electrically isolated areas in the range. Preferably, the active region is provided with column holes shaped to match the openings in the second electrode as a similar triangular lattice arrangement.
H01S 5/34 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
The present invention provides a model mouse. A model mouse according to the present invention has at least the following three or four mutations in the microtubule-binding protein Tau (MAPT): (i) a mutation of an amino acid residue that corresponds to the 320th serine residue of human MAPT, (ii) a mutation of an amino acid residue that corresponds to the 305th serine residue of human MAPT and/or a mutation of an amino acid residue that corresponds to the 301st proline residue of human MAPT, and (iii) a mutation in an intron that corresponds to intron 10 in the gene that codes for human MAPT.
A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A wavelength-variable light source (1) comprises: an oscillation unit (2) that oscillates light; first light output units (4, 5, 6) that variably change the wavelength of the light oscillated by the oscillation unit and output first light having a wavelength in a first wavelength band; a second light optical path (21) that propagates second light having a wavelength different from the first light; and a sum frequency light generation unit (8) that includes a nonlinear optical crystal and combines the first light (L1) output by the first light output units and the second light (L2) propagated in the second light optical path on the same optical axis, causes the combined light to enter the nonlinear optical crystal, and emits sum frequency light (L3) having a wavelength in a second wavelength band shorter than the first wavelength band from the nonlinear optical crystal by sum frequency generation.
The present invention addresses the problem of providing a method with which plants that are not currently used for food, or parts of said plants, are made edible. The present invention also addresses the problem of providing a method for improving the taste of plants that are used for food, or parts of said plants. Provided is a crop or a food/beverage that is made of a plant in which the expression and/or activity of a jasmonic acid defense-related protein is suppressed or inhibited, or part of said plant, or that contains any one thereof, the crop being an edible crop or a feed crop for animals excluding Agromyzidae, and the food/beverage being for humans or being feed for animals excluding Agromyzidae.
A01H 6/00 - Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
A01H 6/20 - Brassicaceae, e.g. canola, broccoli or rucola
A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
The present disclosure provides a composition having NKT cell activation ability that contains cells incubated with a CD1d ligand prior to CD1d introduction. The present disclosure also provides a composition comprising cells, wherein the cells are human-derived cells and express a complex of CD1d and CD1d ligand on the cell surface and in the cell, respectively, and the amount of the complex in the cells is significantly greater than the amount of the complex on the cell surface. The present disclosure further provides a composition capable of further expressing an antigen and further inducing antigen-specific immunity.
A non-transitory computer-readable recording medium has stored therein a prediction program that causes a computer to execute a process including inputting input data of reference timing and information of a lapse of time to a trained self-encoder, predicting an output from the trained self-encoder as noiseless data corresponding to the input data of the reference timing wherein the trained self-encoder has been trained such that an output in a case where data of a reference timing included in training data and information of a lapse of time are input approaches data of a timing corresponding to information of the lapse of time.
In order to set a target value for a physical quantity of an object to be controlled, an acquisition unit (102) in a control device (101) acquires a physical quantity pertaining to an object to be observed and a time differential of the physical quantity pertaining to the object to be observed. A calculation unit (103) calculates the sum of the acquired physical quantity and the product of the acquired time differential and a prediction coefficient. A setting unit (104) sets, as the target value for the physical quantity pertaining to the object to be controlled, an upper limit value if the calculated sum exceeds the upper limit value, a lower limit value if the calculated sum is less than the lower limit value, and the calculated sum if the calculated sum is equal to or greater than the lower limit value and equal to or less than the upper limit value. The control device (101) repeats the acquisition by the acquisition unit (102), the calculation by the calculation unit (103), and the setting by the setting unit (104).
The present invention provides: a fluorinated compound in which a group represented by general formula (1) (wherein n represents an integer of 1-7; and the black dot represents a bond) is linked, via a linking group, to a functional molecule that acts in cells, and the functional molecule is a low-molecular-weight compound having a molecular weight of 200-1,000 Da; a pharmaceutical composition which contains the fluorinated compound; and a method for transporting a fluorinated compound in cells, the method comprising culturing cells in a culture medium containing the fluorinated compound to transport the fluorinated compound into the cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A method for producing a chain-shaped unsaturated carboxylic acid compound or a geometric isomer thereof, having at least two carbon-carbon double bonds, including the steps of: removing, from a chain-shaped unsaturated carboxylic acid compound or a geometric isomer thereof having an amino group and a carbon-carbon double bond at a terminus, that amino group, in the presence of phenylalanine ammonia lyase, and further forming a carbon-carbon double bond.
An object of the present invention is to provide a fluorescent probe that can be used in an enzyme activity detection method. According to the present invention, there is provided a fluorescent probe for detecting a hydrolase, the fluorescent probe containing a compound having at least one water-soluble substituent selected from the group consisting of —CO2H, —PO3H2, and —SO3H and represented by General Formula (II), or a salt thereof. The fluorescent probe of the present invention can be used in an enzyme activity detection method using a microdevice.
An object of the present invention is to provide a fluorescent probe that can be used in an enzyme activity detection method. According to the present invention, there is provided a fluorescent probe for detecting a hydrolase, the fluorescent probe containing a compound having at least one water-soluble substituent selected from the group consisting of —CO2H, —PO3H2, and —SO3H and represented by General Formula (II), or a salt thereof. The fluorescent probe of the present invention can be used in an enzyme activity detection method using a microdevice.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
The present disclosure relates to: a labeled collagen IVα1 protein; a labeled collagen IVα2 protein; nucleic acids encoding said proteins; and animals having said nucleic acids. The present disclosure also relates to a method for observing the labeled collagen IVα1 protein or the labeled collagen IVα2 protein in the animals.
This fluorescence observation device comprises: an excitation light source that irradiates an observation target with excitation light; an imaging unit that captures an observation image using fluorescence emitted by the observation target excited by the excitation light; a light guide optical system that guides the fluorescence to the imaging unit; a fluorescence filter that is disposed on the light incident side of the light guide optical system and transmits light in a wavelength range including the wavelength of the fluorescence; and a light shielding member disposed on the light incident side of the fluorescence filter. The light shielding member shields light incident on the fluorescence filter from a direction intersecting the normal of the fluorescence filter.
This method for determining the risk of a subject developing heart failure is characterized by: including a step for preparing a data list including effect alleles and effect sizes of genetic polymorphism, a step for acquiring genetic information on the subject, a step for calculating a heart failure risk score from genetic information of the subject based on information pertaining to effect alleles and effect sizes of genetic polymorphism in the data list, and a step for determining the risk of heart failure based on the risk score; the data list including genomic analysis results for heart failure in a European and American population, genomic analysis results for heart failure in a population other than Europeans and Americans, genomic analysis results on measurement values related to heart failure subtype, and genomic analysis results on diseases related to heart failure; and the risk score being a combination of the risk scores calculated from these data lists.
Provided is a method for inducing the differentiation of pluripotent stem cells which are obtained by suspension culture with high quality and/or high efficiency. The present invention pertains to a method for producing differentiated cells, the method comprising: a step in which thermal stimulation is applied to pluripotent stem cells after suspension culture of the pluripotent stem cells; a step in which the pluripotent stem cells are subsequently seeded in a culture medium that is different from a culture medium used in the suspension culture; and a step in which agregate mass formation and differentiation induction of the seeded pluripotent stem cells are performed.
This variable-wavelength light source includes: a light output unit that outputs light, the wavelength of the outputted light being variable; a first optical amplification unit that amplifies the light outputted by the light output unit; a filter unit that filters the light amplified by the first optical amplification unit; and a second optical amplification unit that amplifies the light filtered by the filter unit. The first optical amplification unit has a gain on a first-wavelength side that is higher than the gain on a second-wavelength side, the second wavelength being different from the first wavelength. The second optical amplification unit has a gain on the second-wavelength side that is higher than the gain on the first-wavelength side. The filter unit attenuates the natural radiation amplified light.
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
G02F 1/365 - Non-linear optics in an optical waveguide structure
H01S 3/23 - Arrangement of two or more lasers not provided for in groups , e.g. tandem arrangement of separate active media
25.
WAVELENGTH CONVERSION OPTICAL SYSTEM AND PULSE LIGHT GENERATION DEVICE
This wavelength conversion optical system includes: a wavelength conversion element in which different light incident positions have different wavelength conversion bands; and a wavelength-specific optical path setting unit for adjusting an optical path for each wavelength band so that light to be converted to the intended wavelength band hits the corresponding incident position in the wavelength conversion element.
A scanning microscope disclosed herein comprises: a pulse light generation device (or a pulse light generation device) that emits excitation light toward a sample, wherein the excitation wavelength of the excitation light is switched for each pulse; and a detector that detects fluorescence from a cell mass S irradiated with the excitation light and outputs a detection signal. The sensor bandwidth of the detector is adjusted so that the detection signal attenuates within a pulse-off period of the excitation light.
The purpose of the present invention is to provide a polymer blend exhibiting excellent marine biodegradability even when containing a biodegradable resin having poor biodegradability in a marine environment. The present invention provides a marine biodegradable polymer blend comprising: a polyester-based polymer A having a structural unit (A) derived from a succinic acid, a structural unit (B) derived from a C7 or higher dicarboxylic acid, and a structural unit (C) derived from an aliphatic diol; and a biodegradable polymer B, wherein the polyester-based polymer A and the biodegradable polymer B are in a compatible or incompatible state.
A pulse light generation device 1 comprises: an oscillator 2 for oscillating an ultrashort pulse light L; a stretcher fiber 7 for widening the time width of the ultrashort pulse light L; a fiber amplifier 8 for amplifying the ultrashort pulse light L the time width of which has been widened by the stretcher fiber 7; and a compressor 9 for compressing the time width of the ultrashort pulse light L which has been amplified by the fiber amplifier 8. The stretcher fiber 7 is configured by combining a first fiber 71 for widening the time width of the ultrashort pulse light L with a first characteristic, and a second fiber 72 for widening the time width of the ultrashort pulse light L with a second characteristic which is different from the first characteristic.
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
G02F 1/11 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on acousto-optical elements, e.g. using variable diffraction by sound or like mechanical waves
The present invention provides: an agent for reducing the concentration of a protein in blood, the agent containing Pediococcus acidilactici; and a food, a feed, and a medicine each of which is for reducing the concentration of a protein in blood and contains the agent for reducing the concentration of a protein in blood or Pediococcus acidilactici.
The purpose of the present invention is to provide a novel method for increasing the number of newly generated neurons in the adult brain, and to provide a polynucleotide, a vector, and a pharmaceutical composition for use in the method. The present invention provides: a polynucleotide characterized by including (A) the nucleic acid sequence of the Plagl2 gene, (B) an miR-shRNA (microRNA adapted short hairpin RNA) nucleic acid sequence for the Dyrk1a gene, and (C) a promoter sequence operatively connected to the nucleic acid sequences; a vector including the polynucleotide; and a pharmaceutical composition including the polynucleotide and the vector.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
To improve the luminous efficiency of a UV light-emitting device, the UV light-emitting devices disclosed herein have an AlGaN-based crystal or an InAlGaN-based crystal, and comprise an emission layer, at least one electron blocking layer, a first p-type doped layer, and a composition gradient layer in which the Al composition ratio varies depending on the position over a thickness direction of the layer stack, stacked in this order in the direction of the flow of electrons. The Al composition ratio varies depending on the position over the thickness direction in the composition gradient layer. The UV light-emitting devices are implemented as UV-region light-emitting diodes and laser diodes.
A quantum device includes a filter having a plurality of notches in a first frequency band lower than a second frequency band, a first qubit that resonates in the first frequency band, and a second qubit that resonates in the second frequency band. The first qubit is input with a signal having a frequency at which the first qubit resonates via the filter to control a state of the first qubit when executing a one-qubit gating, and is input with a signal having a frequency at which the second qubit resonates via the filter to control a state of the second qubit according to a quantum state of the first qubit when executing a two-qubit gating.
A decoding device 1 decodes measurement results of a concatenated quantum code in which a plurality of quantum codes are concatenated, the decoding device including: a level 1 minimum distance candidate calculation unit 11 that, when the number of concatenated quantum codes is L, obtains a minimum distance, which is the minimum value of the Hamming distance between a code word and a measurement result, for each level 1 code block, and selects an encoded bit string corresponding to the minimum distance of each level 1 code block as a minimum distance candidate for each level 1 code block; a level i minimum distance candidate calculation unit 14 that, for i = 2,..., L, obtains the minimum distance for each level i code block by using a level (i-1) minimum distance and minimum distance candidate, for each level i encoded block consisting of a plurality of level (i-1) encoded blocks, and selects an encoded bit string corresponding to the minimum distance of each level i code block as a minimum distance candidate for each level i code block; and an output unit 20 that selects and outputs one of the level L minimum distance candidates.
H03M 13/19 - Single error correction without using particular properties of the cyclic codes, e.g. Hamming codes, extended or generalised Hamming codes
G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
1−xx2212−y−δyδ2222. X is at least one element selected from the group consisting of Cr, Sb, In, and V. The relationship 0 ≤ x ≤ 1 is satisfied. The relationships 0 < y ≤ 2 and 0 ≤ δ ≤ 1, or 0 ≤ y ≤ 2 and 0 < δ ≤ 1, are satisfied. The film has a film thickness of at least 1.0 nm and less than 70 μm.
This method for producing mesenchymal cells of the ventral hindgut mesoderm comprises: culturing pluripotent stem cells in an induction medium A containing a TGF-β inhibitor, a Wnt agonist, and a fibroblast growth factor to induce differentiation into epiblast-like cells; culturing the epiblast-like cells in an induction medium B containing a Wnt agonist, a fibroblast growth factor, and retinoic acid to induce differentiation into caudal epiblast-like cells; culturing the caudal epiblast-like cells in an induction medium C containing a Wnt agonist, a bone morphogenetic protein, and a TGF-β family member to induce differentiation into posterior primitive streak cells; and culturing the posterior primitive streak cells in an induction medium D containing a Wnt agonist, a fibroblast growth factor, a bone morphogenetic protein, and a hedgehog signaling agonist to induce differentiation into mesenchymal cells of the ventral hindgut mesoderm.
There is provided a travelling-wave parametric amplifier including: a plurality of group cells each including a plurality of unit cells, wherein the plurality of unit cells include: a transmission line that extends along a predetermined direction; and non-linear inductance elements and shunt capacitors arranged along the transmission line, wherein a respective group cell of the plurality of group cells comprises a periodic structure in which the non-linear inductance elements and the shunt capacitors periodically change along the transmission line, and wherein the plurality of group cells comprise a modulation structure in which the non-linear inductance elements and the shunt capacitors modulate along the transmission line.
The present invention provides a catalyst-layer-equipped electrolyte membrane and an application of the same, said catalyst-layer-equipped electrolyte membrane comprising: an anode catalyst layer containing an ionomer and an anode catalyst component that is composed of iridium-containing manganese dioxide, the molar ratio of iridium to manganese in the anode catalyst component being 0.011-0.182, and the logarithm log(amount of ionomer/amount of anode catalyst component) of the ratio of the amount of the ionomer to the amount of the anode catalyst component being −1.40 to −0.46; a proton exchange membrane; and a cathode catalyst layer.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
C25B 9/77 - Assemblies comprising two or more cells of the filter-press type having diaphragms
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
C25B 11/057 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the substrate or carrier material consisting of a single element or compound
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
38.
Cell Population for Transplantation and Method for Producing Same
An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.
In order to provide an IR-QCL element which utilizes the characteristics of a ZnO-based semiconductor material, the present disclosure discloses a quantum cascade laser element 1000 that has a plurality of unit structures 10U in each of which a well layer of ZnO or ZnMgO and a barrier layer of ZnMgO or MgO are alternately and repeatedly stacked. Each unit structure includes a light emitting layer 10E and a continuum layer 10C. The light emitting layer includes: an upstream well layer 10W1 that is composed of a step quantum well having a first layer and a second layer, which have different MgO composition ratios from each other; and a downstream well layer 10W2 that has a smaller MgO composition ratio than any of the first layer and the second layer.
H01S 5/347 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIBVI compounds, e.g. ZnCdSe-laser
40.
NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM, INFORMATION PROCESSING APPARATUS, AND PREDICTION CONTROL METHOD
A non-transitory computer-readable recording medium has stored therein a prediction control program that causes a computer to execute a process. The prediction control program is a prediction control program of a structure prediction model that predicts a three-dimensional structure of an organic compound from sequence information on the organic compound. The process comprises changing an intermediate feature value of the structure prediction model so that a difference between first limiting information and second limiting information different from the first limiting information is lessened, the first limiting information corresponding to a predicted structure output as a prediction result from the structure prediction model.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Provided are: a novel stem cell activator; a topical skin preparation containing the stem cell activator; and a skin cosmetic containing the stem cell activator. The stem cell activator according to the present invention contains, as an active ingredient, at least one compound selected from compounds represented by the following formula (1) (including optical isomers), salts of these compounds, and hydrates thereof. In the formula, R1and R2represent a hydrogen atom or a hydrocarbon group. R3 represents a hydrogen atom or an organic group. n represents an integer of 1 or more. The hydrocarbon group may be substituted.
To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).
Provided is a concentration difference power generation system 100 which utilizes a concentration difference liquid including a first liquid 22 and a second liquid 42 having a concentration lower than that of the first liquid, in order to provide renewable energy power generation which utilizes sunlight and easily adapts power generation amount to demand. The first liquid is in contact with a metamaterial absorber 10. Upon irradiation with sunlight, the metamaterial absorber accelerates evaporation of a solvent from the first liquid in accordance with energy from the sunlight, and increases the concentration of the solute of the first liquid. The concentration difference power generation system additionally comprises, as needed: a first liquid storage unit 30 and an evaporation pool 20 for the first liquid 22; a second liquid storage unit 40 for supplying the second liquid 42; and a concentration difference power generation unit 50.
The present invention facilitates catalyst designing. A catalyst design system according to one embodiment of the present invention is a system for designing a catalyst that promotes a specific chemical reaction, and comprises: an acquisition unit that acquires information for identifying a chemical reaction that is specified by a user and that is to be promoted by the catalyst; an extraction unit that extracts, from a database, information pertaining to a molecular structure included in the chemical reaction identified on the basis of the acquired information, and a state quantity in the process of the chemical reaction; a learning unit that performs machine learning using the information pertaining to the molecular structure and the state quantity that have been extracted from the database, to generate a prediction model; a prediction unit that uses the prediction model to predict a state quantity from the information pertaining to the molecular structure specified by the user; and an identification unit that identifies a dominant factor of the predicted state quantity and displays the dominant factor.
G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
G16C 20/70 - Machine learning, data mining or chemometrics
45.
DEVICE FOR ENSURING RELIABILITY OF SERVICE BY DATA SCIENCE, METHOD FOR ENSURING RELIABILITY OF SERVICE BY DATA SCIENCE, AND COMPUTER PROGRAM FOR CAUSING COMPUTER TO EXECUTE SAID METHOD
Provided is a device for ensuring the reliability of a service by data science, the device comprising: an acquisition unit that, for each of a plurality of deviations considered to be likely to occur in a service, acquires grounds information indicating a plurality of grounds for resolving each deviation, the grounds information being agreed upon between a plurality of stakeholders who exchange the service; a generation unit that determines a plurality of first relationships between the plurality of grounds and mutually associates the plurality of grounds on the basis of the plurality of first relationships, thereby generating self-describing information units in which each deviation is accounted for; and a calculation unit that determines a plurality of second relationships between the plurality of self-describing information units generated for each of the plurality of deviations, calculates a feature amount for each of the plurality of self-describing information units, and mutually associates the plurality of feature amounts on the basis of the plurality of second relationships, thereby calculating a reliability feature amount representing the reliability of the service.
MOVING IMAGE PROCESSING DEVICE FOR PROVIDING MOVING IMAGE INDICATING BEAT OF MUSICAL PIECE, MOVING IMAGE PROCESSING METHOD, PROGRAM, AND INFORMATION RECORDING MEDIUM
A moving image processing device (101) provides a moving image indicating the beat of a musical piece being reproduced. A setting unit (102) sets a vicinity position in the vicinity of a predetermined position in a screen. An input unit (103) receives an input of a beat moving image reproduced in synchronization with the musical piece which is reproduced in accordance with a control signal output from a DJ controller. The beat moving image is a moving image in which a beat object associated with each beat of the musical piece moves in the screen, and the beat object associated with the relevant beat reaches the predetermined position in the screen at a beat timing at which the relevant beat of the musical piece is reproduced. Each time a frame of the beat moving image is input, a drawing unit (104) draws a timing object at the set vicinity position in the input frame. An output unit (105) outputs a frame in which the timing object is drawn as a frame of a timing moving image. If a detection unit (106), which may be omitted, detects a scratch operation, the drawing unit (104) also draws a scratch object.
The invention aims to provide a medicament having a superior anti-malignant tumor effect and a method for treating a malignant tumor therewith. In particular, the medicament contains a bacterium and a liposome encapsulating an anti-malignant tumor agent in combination.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
According to an aspect, a fluorescence detection device includes: a light source configured to irradiate a sample with excitation light in a circularly polarized state; a sample holder configured to hold the sample; a cholesteric liquid crystal layer configured to transmit fluorescence emitted by the sample due to the excitation light and reflect the excitation light; and a sensor configured to detect the fluorescence transmitted through the cholesteric liquid crystal layer.
The present invention addresses the problem of providing a tough, fluorescent self-repairing elastomer. The present invention provides a copolymer having a first unit and a second unit that are at least two different types of olefin-derived repeating units, and a third unit that is at least one type of compound-derived repeating unit having at least one type of light-emitting unit in a side chain.
C08F 210/00 - Copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
C08F 212/00 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
C08F 212/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms
ATOM TRAP DEVICE, ATOM COOLING DEVICE, SPECTROSCOPIC DEVICE, OPTICAL LATTICE CLOCK, QUANTUM COMPUTER, COIL, ATOM TRAP METHOD, ATOM COOLING METHOD, AND SPECTROSCOPIC METHOD
This atom trap device 10 for trapping atoms comprises an atom trap unit 16 on which an atomic gas beam is incident. The atom trap unit 16 includes a plurality of optical elements that form a laser light group 18, and a magnetic field generation unit 22. The magnetic field generation unit 22 is provided with at least two spiral coils and, if necessary, a tapered solenoid coil, and optimizes a magnetic field in a guide direction. The spiral coils are configured so that the tip becomes thinner and the winding density becomes sparse as the atoms advance in the direction in which the atoms are guided. The spiral coils are arranged so as to face each other so that an interval therebetween becomes narrower as the atoms advance in the direction in which the atoms are guided. The tapered solenoid coil generates a magnetic field that optimizes the guiding of the atoms and the laser cooling during the guiding by adjusting the component in the direction in which the atoms of the magnetic field generated by the spiral coils are guided. The atom trap unit 16 may also include a baseball coil instead of the spiral coils and the tapered solenoid coil.
The purpose of the present invention is to provide a novel prophylactic and/or therapeutic agent for a neurodegenerative disease, which can increase the number of new neurons in an adult brain. The present invention is a prophylactic and/or therapeutic agent for a neurodegenerative disease, the agent containing, as an active ingredient, an inhibitor of any one of genes shown in table 1 or a protein derived from any one of the genes.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to: a catalyst precursor for ammonia synthesis, the catalyst precursor including a nitrogen activation catalyst precursor loaded body (A1) in which a precursor of a catalyst component for activating nitrogen is supported by a carrier that is composed of a porous body that has a specific surface area of 1,000 m2/g or more, and a hydrogen activation catalyst precursor loaded body (B1) in which a precursor of a catalyst component for activating hydrogen is supported by a carrier that is different from the above-described carrier; and a catalyst for ammonia synthesis obtained by activating the catalyst precursor.
B01J 35/73 - Catalysts, in general, characterised by their form or physical properties characterised by their crystalline properties, e.g. semi-crystalline having a two-dimensional layered crystalline structure, e.g. layered double hydroxide [LDH]
B01J 37/02 - Impregnation, coating or precipitation
A gate-definition type quantum-dot structure 1 includes: a quantum-well substrate for confining electrons in a quantum dot; a lead-inducing gate 12 for applying a voltage to a lead 17, which is a supply source of the electrons to the quantum dots, and extending the lead 17 to the vicinity of the quantum dots; a lead-quantum dot barrier-gate 13 for controlling entry and exit of the electrons between the lead 17 and the quantum dots; a plunger gate 14 for adjusting the number of the electrons in the quantum dot; an inter quantum-dot barrier-gate 15 for adjusting strength of tunnel coupling between the adjacent quantum dots; a screening gate 11 for shielding the voltage applied to the lead-quantum dot barrier-gate 13, the plunger gate 14, and the inter quantum-dot barrier-gate 15; and a charge meter for detecting the state of the quantum bit represented by the electrons confined in the quantum dot. The screening gate 11, the lead-inducing gate 12, the lead-quantum dot barrier-gate 13, the plunger gate 14, and the inter quantum-dot barrier-gate 15 are laminated on the quantum-well substrate. The lead 17 is tunnel-coupled with all the quantum dots.
H10D 62/81 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials of structures exhibiting quantum-confinement effects, e.g. single quantum wellsSemiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials of structures having periodic or quasi-periodic potential variation
54.
FABRICATION METHOD FOR ELECTRIC CIRCUIT DEVICE, AND QUBIT DEVICE
Provided is a fabrication method for an electric circuit device, the fabrication method including forming a conductive layer on a substrate, forming a bottom resist layer on the conductive layer, forming a cover layer on the bottom resist layer, forming a top resist layer on the cover layer, forming a contact hole in the substrate by using the top resist layer as a mask, forming a first undercut structure by etching the bottom resist layer below the cover layer, and forming a contact metal layer on a sidewall of the contact hole and above a front surface of the substrate after the first undercut structure is formed.
The present disclosure provides at least one of an iridium-containing manganese oxide that exhibits high oxygen-generating electrode catalytic activity in a water electrolysis method, a catalyst that contains the same, an electrode that contains the catalyst, and a water electrolysis method that uses the electrode. With respect to the iridium-containing manganese oxide according to the present invention, the molar ratio of iridium to manganese is not less than 0.001 but 0.250 or less. In one embodiment, the manganese oxide is manganese dioxide that has a β-type crystal structure. In another embodiment, the ratio of the lattice constant in the a-axis direction to the lattice constant in the c-axis direction is not less than 1.420 but less than 1.521.
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
A method for producing methacrylic acid, comprising: decarboxylating mesaconic acid or an isomer thereof in the presence of protocatechuate decarboxylase.
To attain the object of assisting childcare behaviors for promoting stopping of crying of an infant or sleep of an infant, included are: a sensor information acquisition unit (101) that acquires sensor information from a sensor that detects an infant's state; a calculation unit (103) that calculates, on the basis of the sensor information, at least one of heart rate information (IBI) and an infant state score (ISS); an output unit (104) that outputs, in real time, information indicating at least one of the IBI and the ISS; and a notification unit (105) that outputs notification information for notifying a user of a childcare behavior to be performed to promote stopping of crying of the infant or sleep of the infant on the basis of at least one of the length of time elapsed since start of holding and walking has been detected, the IBI, and the ISS.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
58.
TERAHERTZ WAVE DIFFUSER AND METHOD FOR MANUFACTURING THE SAME
This invention disrupts a phase of an incident THz wave. An embodiment of the present disclosure provides a terahertz wave diffuser 100 comprising a dispersion medium 2 and a particulate dispersoid 10. The dispersion medium transmits the incident terahertz wave. The particulate dispersoid is made up of particles 1 each comprising a microstructure and a material responding to the incident terahertz wave, and is supported by being dispersed in the dispersion medium. The present disclosure also provides a method for manufacturing the terahertz wave diffuser.
The invention relates to a complex comprising a first component: (i) a carrier peptide comprising a cell-penetrating sequence and a polycation sequence: and a second component (ii) a ribonucleic acid (RNA), PNA and/or protein, wherein the carrier peptide is a cyclic peptide comprising at least 2 cysteine residues bridged by a disulphide bond.
Provided is a method for visualizing the denatured state or aggregated state of proteins as a means for detecting denatured or aggregated proteins with high sensitivity, which can be applied even to a protein mixed system, the method comprising a steps of bringing a protein into contact with a nitrobenzoxadiazole derivative, and a steps of detecting the fluorescence of a reaction product of the nitrobenzoxadiazole derivative and the protein.
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
61.
METHOD FOR PRODUCING MODIFIED NUCLEIC ACID MOLECULE-PEPTIDE COMPLEX, NUCLEIC ACID DISPLAY METHOD OR RIBOSOME DISPLAY METHOD
The method of the present disclosure is a method for producing a modified nucleic acid molecule-peptide complex in which a functional molecule has been introduced into the peptide moiety of a nucleic acid molecule-peptide complex in which a nucleic acid molecule and a peptide encoded by the nucleic acid molecule are linked.
A storage device (10) for storing a target substance (1), which is an irradiation target of a particle beam, comprises: a target container (3) in which an internal space (3a) having an upper opening (3a1) and a lower bottom surface (3a2) is formed; and a sealing member (5a) which is attached to the target container (3) so as to close the opening (3a1) and seal the internal space (3a), and can transmit the particle beam. The bottom surface (3a2) includes a recess (D) recessed downward, and the target substance (1) is disposed in the recess (D).
G21G 1/10 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by bombardment with electrically-charged particles
G21G 1/08 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation accompanied by nuclear fission
A neutron convergence device (1) comprises a plurality of units (10) connected in the axial direction and a neutron supermirror having a prescribed rotational curved surface shape. Each of the plurality of units (10) includes: a plurality of mirror segments (121) forming a mirror part (12) that constitutes a part of the neutron supermirror having the prescribed curved surface shape; a vacuum chamber (11); and a coupling flange (13) to which the plurality of mirror segments (121) and the vacuum chamber (11) are attached. Each of the plurality of mirror segments (121) is provided with a flange part (122) at one end, and the vacuum chamber (11) is provided with a first flange part (112) at one end and a second flange part (113) at the other end.
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
B23B 5/00 - Turning-machines or devices specially adapted for particular workAccessories specially adapted therefor
B24B 29/02 - Machines or devices for polishing surfaces on work by means of tools made of soft or flexible material with or without the application of solid or liquid polishing agents designed for particular workpieces
G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
The present invention aims to provide an NKT cell ligand-containing preparation that can artificially activate NKT cells in a living body and is useful as an anti-malignant tumor agent and the like.
The present invention aims to provide an NKT cell ligand-containing preparation that can artificially activate NKT cells in a living body and is useful as an anti-malignant tumor agent and the like.
A liposome composition containing a glycolipid selected from the group consisting of a compound represented by the formula (I), a compound represented by the formula (II), and salts thereof:
the formula (I):
The present invention aims to provide an NKT cell ligand-containing preparation that can artificially activate NKT cells in a living body and is useful as an anti-malignant tumor agent and the like.
A liposome composition containing a glycolipid selected from the group consisting of a compound represented by the formula (I), a compound represented by the formula (II), and salts thereof:
the formula (I):
wherein each symbol is as defined in the specification, the formula (II):
The present invention aims to provide an NKT cell ligand-containing preparation that can artificially activate NKT cells in a living body and is useful as an anti-malignant tumor agent and the like.
A liposome composition containing a glycolipid selected from the group consisting of a compound represented by the formula (I), a compound represented by the formula (II), and salts thereof:
the formula (I):
wherein each symbol is as defined in the specification, the formula (II):
wherein each symbol is as defined in the DESCRIPTION.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
To provide a method for producing induced pluripotent stem cells (iPS cells) that can initialize somatic cells without using feeder cells or a substrate. For production of iPS cells, the following steps are carried out: I. introducing an initialization gene into a somatic cell; and II. performing initialization and amplification culture of the cell into which the gene has been introduced, in a liquid medium comprising at least one of a protein kinase Cβ (PKCβ) inhibitor and a WNT inhibitor under a suspension culture condition.
Magneto-Optical Trap Device, Physics Package, Physics Package for Optical Lattice Clock, Physics Package for Atomic Clock, Physics Package for Atomic Interferometer, Physics Package for Quantum Information Processing Device, and Physics Package System
In this magneto-optical trap device, five laser beams are irradiated in a trap space in which atoms are trapped. Of the five laser beams, three laser beams (laser beams a1, a2, a3) pass through the inside of the same plane (Z plane) and are irradiated in the trap space. The two laser beams that intersect that plane (laser beams a4, a5) are irradiated in the trap space. The laser beam a1 is used together as a slowing laser beam b for Zeeman slower.
G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
H03L 7/26 - Automatic control of frequency or phaseSynchronisation using energy levels of molecules, atoms, or subatomic particles as a frequency reference
Provided is a novel compound having excellent antiviral activity. Provided is a compound represented by formula (I) (In the formula, R2and R1or R3, together with a carbon atom on the benzene ring to which these are bonded, form a carbon ring or heterocycle condensed with the benzene ring. R1or R3that does not form said ring, R4, R5, R6and R71-62-61-61-61-61-6 alkoxy-carbonyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted acyl group). Also provided is an antiviral agent containing said compound.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C01F 11/00 - Compounds of calcium, strontium, or barium
C04B 35/01 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides
C25B 13/07 - DiaphragmsSpacing elements characterised by the material based on inorganic materials based on ceramics
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
H01B 1/08 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances oxides
H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
H01M 8/124 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte
H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides
A molecular dynamics computation device includes a processor that executes a procedure. The procedure includes: executing machine learning of a first force field for predicting energy for an input structure using, as training data, a structure of a coarse-grained model resulting from coarse-graining an all-atom model sampled by molecular dynamics computation based on an all-atom force field and an energy corresponding to the all-atom model structure; and computing molecular dynamics of a coarse-grained model based on a second force field obtained by combining the first force field that has been subjected to machine learning and an energy based on a coarse-grained model structure.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
70.
METHOD FOR ASSISTING DIAGNOSIS OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, AND METHOD FOR SCREENING FOR THERAPEUTIC AGENT FOR MULTIPLE SCLEROSIS
NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (Japan)
RIKEN (Japan)
Inventor
Yamamura Takashi
Sato Wakiro
Takewaki Daiki
Suda Wataru
Masuoka Hiroaki
Kiguchi Yuya
Kurokawa Rina
Ogata Yusuke
Abstract
The present invention relates to a method for assisting the diagnosis of secondary progressive multiple sclerosis, the method including: a step in which the relative abundance of Tyzzerella nexilis in a fecal sample collected from a subject is measured; and a step in which, when the relative abundance of Tyzzerella nexilis is larger than that in a fecal sample collected from a normal person, it is determined that the subject has been affected with or is potentially affected with secondary progressive multiple sclerosis. The Tyzzerella nexilis is a bacterium that carries genome DNA having a 97% or higher average nucleotide identity with the nucleotide sequence for the genome DNA represented by SEQ ID NO: 1.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention provides a system for quantifying the effects of a change of a condition pertaining to a subject for a prescribed period, wherein the change, which occurs for the prescribed period, includes at least a change from a first condition to a second condition. The system comprises: a reception means which receives data measured from the subject, the data including first data measured from the subject in the first condition and second data measured from the subject in the second condition; a derivation means which derives, from the received data, at least a first component that represents an accumulation of a load on the subject for the prescribed period and a second component that varies following the change; and an output means which outputs at least one of the derived first component and second component.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
72.
TRANSLUCENT MAGNETIC MATERIAL, OPTICAL ELEMENT AND OPTICAL DEVICE
The present invention provides a translucent magnetic material having excellent optical characteristics. The translucent magnetic material comprises a plurality of magnetic particles which include a plurality of FeCo particles, and a translucent material in which the plurality of magnetic particles are dispersed. The translucent material includes a ceramic material which contains a compound of fluorine and at least one element from among group III, group IV and group V, and a metal material which is disposed in a region between the plurality of FeCo particles and the ceramic material.
G02F 1/09 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on magneto-optical elements, e.g. exhibiting Faraday effect
G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/20 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metals or alloys in the form of particles, e.g. powder
H01F 10/16 - Thin magnetic films, e.g. of one-domain structure characterised by magnetic layers characterised by the composition being metals or alloys containing cobalt
H01F 41/18 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates by cathode sputtering
73.
CONTAINER FOR PRODUCING TENSION-APPLIED THREE-DIMENSIONAL ARTIFICIAL SKIN AND PRODUCTION METHOD THEREOF
The culture insert container has a lower culture container having a bottom portion equipped with a porous membrane and a sidewall, and having an upper insertion fixture having a cylindrical sidewall that is inserted into said lower culture container. The cylindrical sidewall has a land arranged so as to protrude from a top end of the sidewall of the lower culture container at a location such as will cause a top surface of said porous membrane and a bottom end portion of the cylindrical sidewall which is inserted within the lower culture container to be maintained in a noncontacting state. A land is arranged at an outer surface of the cylindrical sidewall so as to cause a constant distance to be maintained between an inner surface of the sidewall of the lower culture container and the outer surface of the cylindrical sidewall.
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
74.
Atom Beam Generation Device, Physics Package, Physics Package for Optical Lattice Clock, Physics Package for Atomic Clock, Physics Package for Atomic Interferometer, Physics Package for Quantum Information Processing Device, and Physics Package System
An atom beam generation device includes an atomic oven including a reservoir in which a sample is contained, a deceleration unit, and coil units. The deceleration unit includes a bore through which an atomic beam and a slowing laser beam pass, and decelerates an atomic beam emitted from the atomic oven by means of slowing laser beam and a magnetic field. The coil units supply Joule heat to the atomic oven, and generate a magnetic field in the deceleration unit.
A learning method includes: causing an observer to perceive information to be compared by the observer from among a plurality of pieces of perceivable information; acquiring evaluation for the information made by the observer; and rating the plurality of pieces of information based on the evaluation made by the observer for the plurality of pieces of information acquired by a plurality of repetitions of the causing the observer to perceive the information and the acquiring the evaluation.
An object of the present invention is to provide a method capable of detecting activity of an enzyme that strictly recognizes a substrate, such as acetylcholinesterase (AChE). There is provided a method for detecting activity of an enzyme in a biological sample using a microdevice, the method including a step of bringing the biological sample into contact with a substrate analog or a natural substrate, and a compound represented by General Formula (I) below or a salt thereof, wherein the substrate analog or the natural substrate generates a compound A having a thiol group (R—SH), a selenol group (R—SeH), or a poly sulfur atom (R—(S)n-H) (R is a hydrogen atom or an alkyl group, and n is 1 to 5) by a reaction with the enzyme, and fluorescence is observed or measured, the fluorescence being emitted or enhanced from a fluorescent product generated by the reaction of the compound represented by General Formula (I) or the salt thereof with the thiol group, the selenol group, or the poly sulfur atom.
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
C07F 7/08 - Compounds having one or more C—Si linkages
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/46 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase involving cholinesterase
77.
LIGHT EMITTING ELEMENT AND METHOD FOR MANUFACTURING SAME
For the purpose of improving the luminous efficiency of a light emitting element by increasing conduction characteristics, a light emitting element 100 according to an embodiment of the present disclosure includes an AlGaN-based crystal or an InAlGaN-based crystal, and is provided with a light emitting layer 134, at least one electron blocking layer 138, a first Mg-doped layer 140, and a dam layer 150, which are sequentially stacked in this order in the direction of the flow of electrons. The dam layer 150 has a higher Al composition ratio than the first Mg-doped layer. Another embodiment of the present disclosure provides a method for manufacturing a light emitting element that is provided with an Mg-doped layer of any one of a GaN-based crystal, InGaN-based crystal, AlGaN-based crystal, and InAlGaN-based crystal, the method including an activation step for causing an electron catalytic reaction in a first Mg-doped layer so as to activate Mg into an ionized acceptor.
The present invention enhances light extraction efficiency (LEE) in a 230 nm band UVC-LED. This AlGaN-based deep ultraviolet LED having a light emission wavelength λ has a photonic crystal periodic structure in a thickness direction, wherein the distance between an upper part of a quantum well layer and a bottom part of the photonic crystal periodic structure substantially satisfies a resonance condition λ/n of free end reflection. Here, n is the weighted average refractive index of a layer structure existing between the upper part of the quantum well layer and the bottom part of the photonic crystal periodic structure.
H01L 33/10 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a light reflecting structure, e.g. semiconductor Bragg reflector
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
The present invention addresses the problem of elucidating the function of human Mhr1 and providing a method for improving mitochondrial function. Provided is a method for promoting mitochondrial DNA homoplasmy formation or for improving mitochondrial function, the method including introducing a protein having 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO: 1 or DNA or mRNA encoding a protein having 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO: 1 into a cell.
A superconducting coil device includes a superconducting coil and adhesive layer. The superconducting coil includes a superconducting wire wound into a coil shape. An electrical conductivity is imparted to the adhesive layer. The adhesive layer constitutes at least a part of a current bypass for the superconducting coil. The adhesive layer includes a binder. The adhesive layer includes a resistance-decrease suppression structure that imparts the electrical conductivity to the adhesive layer while suppressing a decrease in contact resistance with the superconducting wire.
An objective of the present invention is to provide at least one among: an electrode containing a manganese oxide which suppresses the elution of manganese during water electrolysis without reducing hydrogen productivity; and a method for manufacturing the electrode. The electrode includes a conductive substrate, and an oxygen generating electrode catalyst containing iridium-manganese oxide. The content of iridium per geometric area of the conductive substrate is less than 10 μg/cm2.
C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
Provided is a device for estimating the atomic structure of a biomolecule, the device comprising: a generation unit that generates an image generated on the basis of a target biomolecule; an acquisition unit that acquires a plurality of first candidate structure images on the basis of two-dimensional projection images from a plurality of atomic structures prepared; a global search unit that, on the basis of the similarity between the generated image and the candidate structure images, selects, as a basic candidate structure, a structure having a high degree of structural similarity and/or molecular orientation similarity to the target biomolecule from among the plurality of atomic structure candidate structures; and a local search unit that acquires a plurality of second candidate structure images on the basis of two-dimensional projection images of a plurality of modified atomic structures obtained by modifying the basic candidate structure, and selects, on the basis of the similarity between the second candidate structure images and the generated image, a structure having a high degree of structural similarity and/or molecular orientation similarity to the target biomolecule from among the modified atomic structures.
G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
G16C 20/40 - Searching chemical structures or physicochemical data
This inspecting device is a device for inspecting an inner circumferential surface of an object under inspection that has a cylindrical shape. The device comprises: an inspecting unit for emitting terahertz waves toward the inner circumferential surface and detecting reflected waves of the terahertz waves; and a distance measuring unit for measuring the distance between the inspecting unit and the inner circumferential surface. The inspection target and the distance measuring unit are caused to rotate in the circumferential direction of the object under inspection. Further, the relative axial position of the inspecting unit with respect to the object under inspection is adjusted. Further, the position of the inspecting unit in a plane intersecting the axial direction of the object under inspection can be adjusted. Control of the position adjustment mechanism is performed on the basis of the measurement result from the distance measuring unit such that the center of rotation of a rotation unit is positioned on the central axis of the object under inspection.
G01B 15/04 - Measuring arrangements characterised by the use of electromagnetic waves or particle radiation, e.g. by the use of microwaves, X-rays, gamma rays or electrons for measuring contours or curvatures
84.
FILTER CIRCUIT, QUANTUM DEVICE, QUANTUM COMPUTER, FILTER CIRCUIT MANUFACTURING METHOD, FILTER CIRCUIT ASSEMBLY METHOD, READOUT FREQUENCY FILTERING METHOD, AND QUANTUM BIT DISPERSIVE READOUT METHOD
A filter circuit 1 comprises: a readout resonator 11 that is coupled to data quantum bits; and a filter resonator 12 that is configured and is coupled to an observation line. The readout resonator 11 and the filter resonator 12 are electrically and magnetically coupled by using capacitive coupling and inductive coupling in parallel.
Provided is an electrode exhibiting high oxygen generating electrode catalytic activity as compared with conventional electrodes using manganese-based oxide as an oxygen generating electrode catalyst.
C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
C25B 11/042 - Electrodes formed of a single material
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
(1) The purpose of the present invention is to provide an antitumor agent in which an effect of an immune checkpoint inhibitor is enhanced. (2) The purpose of the present invention is also to provide a drug that could exhibit an effect even under conditions in which no antigen is present. (1) Provided is an antitumor agent obtained by combining an immune checkpoint inhibitor with an NKT cell ligand-containing liposome composition. (2) Also provided is a liposome composition containing an NKT cell ligand and an antigen.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
In order to achieve a charged particle beam sensor capable of measuring beam position with high linearity, provided is a charged particle beam sensor comprising a plurality of electrodes 1-8 that cover a right cylinder side surface. The plurality of electrodes are insulated from each other by a plurality of separation curves which each draw, with respect to a direction along the axis of the right cylinder side surface, a curve from the minimum value to the maximum value of a sine wave relating to a rotation angle in any rotation direction around the axis of the right cylinder side surface. The charged particle beam is disposed so as to pass through the inside of the right cylinder side surface. In a measurement data processing method, a signal wave second-order integral value is calculated.
G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation
88.
METHOD FOR ACQUIRING VALUE OF AUTONOMIC NERVOUS SYSTEM INDEX FOR EVALUATING MENTAL STATE OF SUBJECT, AND METHOD, SYSTEM, AND PROGRAM FOR EVALUATING MENTAL STATE OF SUBJECT
The present invention provides a method for acquiring the value of an autonomic nervous system index for evaluating the mental state of a subject. The method comprises acquiring the value of the autonomic nervous system index of the subject at a first time point and a second time point. The autonomic nervous system index or a calculated value thereof serves as an index of the mental state of the subject. The method is characterized in that the sleep state of the subject at the first time differs from at the second time point. The present invention also provides a method, for example, for evaluating the mental state of a subject on the basis of an acquired value of an autonomic nervous system index or a calculated value thereof.
The purpose of the present invention is to provide a novel HVEM-binding protein. The present invention provides a human HVEM-binding protein comprising at least one immunoglobulin single variable region, wherein: the immunoglobulin single variable region includes complementarity determining regions 1-3 which have the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 3, respectively; and the immunoglobulin single variable region is a humanized VHH. The protein according to the present invention may further comprise a human immunoglobulin Fc region or a human serum albumin-binding protein, and the immunoglobulin Fc region may be an Fc region of human IgG4.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A film deposition method including installing a substrate on a turntable of a spin coating device such that a first main surface faces the turntable, and adding a first liquid having viscosity dropwise onto a second main surface of the substrate; holding the substrate in the same state until the first liquid added dropwise reaches the first main surface side from the second main surface side through a through-hole; otating the substrate together with the turntable; and heating the first liquid together with the substrate.
A method of producing radionuclides includes installation, irradiation, transport, and trapping steps. In the installation step, a target material containing a target nuclide is placed inside a target chamber. In the irradiation step, at least a portion of the target material is irradiated with a quantum beam. In the transport stage, a carrier gas is supplied to the inside of the target chamber and an ambient gas around the target material is sent to the outside of the target chamber through an exhaust pipe. In the trapping step, a trap device connected to the exhaust pipe is configured to trap the radionuclides produced from the target nuclide from the ambient gas. In some cases, a target holding device for quantum beam irradiation comprising a target material container and a rotational drive mechanism is also provided, as well as a quantum beam irradiation system. An example target material container is rotatable.
G21G 1/04 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
G21K 5/08 - Holders for targets or for objects to be irradiated
The present invention provides a plant root system morphology control means which is effective and easy to use. The present invention provides a plant root system morphology control agent comprising 2-aminopimelic acid or a salt or ester thereof.
A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
A01G 7/06 - Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
A01H 3/04 - Processes for modifying phenotypes by treatment with chemicals
A data integration apparatus according to one embodiment includes a controller including a platform for automatically performing a type conversion of an object, an acquisition unit, an interpreter, and an integrator. The acquisition unit acquires each data as a graph in which an object of the platform is a constituent element, or as a collection of information in a language format in which an object is associated with a word. The interpreter performs an interpretation process for converting the constituent element of the graph into a type on a hyponymy-side. The integrator performs an integration process for holding information generated by the interpretation process and information acquired by the acquisition unit, and reflecting the information on the graph. The data integration apparatus operates when the controller repeatedly and automatically performs the interpretation process and the integration process.
G06F 30/12 - Geometric CAD characterised by design entry means specially adapted for CAD, e.g. graphical user interfaces [GUI] specially adapted for CAD
G06F 30/13 - Architectural design, e.g. computer-aided architectural design [CAAD] related to design of buildings, bridges, landscapes, production plants or roads
Provided is an LED having a quantum well structure and comprising: a quantum well layer having a composition AlaGa1-aN (aluminum gallium nitride) (0 < a < 1); and a high-level layer that has a composition AlbGa1-bN (a < b ≤ 1), is adjacent to the quantum well layer, and has an energy level higher than that of the quantum well layer. ΔX, which is the difference between a and b, and the width D [nm] of the quantum well layer satisfy [relational expression 1] D = k/ΔX (where, in the relational expression 1, D > 3, 0 < ΔX < 0.15, and 0.45 ≤ k ≤ 1.25 (unit of the coefficient k is [nm])).
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/14 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a carrier transport control structure, e.g. highly-doped semiconductor layer or current-blocking structure
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01S 5/343 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser
The present invention pertains to: a guide RNA having, on the 5' side of a spacer sequence, a repeat sequence that is cleaved through processing for forming a cascade complex, and not having a repeat sequence or having a sequence that is not cleaved through processing for forming a cascade complex, on the 3' side of the spacer sequence; and a type-I CRISPR-Cas system using the guide RNA.
A sample preparation system (100) includes a position identification section (34) that associates a plurality of cells constituting a cell group with the respective plurality of cells constituting the cell group in which at least a part of junctions between adjacent ones of the plurality of cells is disconnected, in a dispersion process of (i) disconnecting at least the part of the junctions between the adjacent ones of the plurality of cells in the cell group in which the plurality of cells are joined to each other and (ii) dispersing the cell group. This allows the realization of a technique of collecting a cell and specifying the position of the collected cell in an original cell group.
An observation device includes a neutron emission device, a detection device, and a data processing device. The neutron emission device emits neutrons to an inspection object. The detection device detects exit neutrons from the inspection object at one set of detection positions in a peripheral direction around the inspection object, outside the inspection object, and measures the number of the detected exit neutrons for each of the detection positions. The data processing device generates reconstructed cross-sectional data by performing reconstruction processing based on the number of the detected exit neutrons at each of the one set of detection positions. The reconstructed cross-sectional data represent a two-dimensional distribution of a neutron reaction rate in an imaginary cross-section of the inspection object.
G01N 23/05 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using neutrons
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventor
Yamamoto Michihisa
Takada Shintaro
Bauerle Christopher
Abstract
Provided is a quantum computer, including: an input unit for inputting an electron wave packet; a propagation unit that propagates the electron wave packet in a predetermined direction and has a loop-like loop path; and a qubit generation unit that generates a time-bin qubit by using the electron wave packet.
Provided is a method for efficiently preparing a library. The method for preparing a library includes the steps of (a) synthesizing single-stranded cDNA from 10 pg or more of template RNA; (b) synthesizing double-stranded cDNA from the single-stranded cDNA; and (c) preparing a library using the double-stranded cDNA that is unpurified.
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
RIKEN (Japan)
Inventor
Furukawa Taiki
Oyama Shintaro
Yokota Hideo
Abstract
This information processing device is provided with a state information acquisition unit and an analysis processing unit. The state information acquisition unit continuously acquires objective state information of a patient suffering from a disease, and subjective state information based on the patient's subjectivity. On the basis of the objective state information and the subjective state information, and using a predetermined information processing technique, the analysis processing unit continuously executes predetermined analysis processing including setting of a policy recommended to be executed by the patient in order to improve the symptom of the disease, and outputs the result of the analysis processing in a manner that can be perceived by the patient.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
patents
